Home › Chronic Lymphocytic Leukemia › NCT06788639
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Non-interventional Cohort Study of Patients Treated With Liso-cel (Lisocabtagene Maraleucel) for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Post-Marketing Setting
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: • Participants must have been treated in the post-marketing setting with ≥1 infusion of lisocabtagene maraleucel used for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) within the approved indication and dosage per the United States Prescribing Information (USPI) and product specifications approved for commercial release in the USA Exclusion Criteria: * Participants known to be participating in investigational studies at the time of lisocabtagene maraleucel infusion * Patients treated with non-conforming CAR T-cell product
About the study
The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities
What is being tested
- Lisocabtagene maraleucel (biological)
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Participants: 300 · Started: Feb 4, 2025
Contact the study team
- BMS Study Connect Contact Center www.BMSStudyConnect.com · Phone: 855-907-3286
Official record on ClinicalTrials.gov — NCT06788639
Locations in the U.S.
| Wisconsin | Center for International Blood and Marrow Transplant Research (CIBMTR), Milwaukee |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.